NASDAQ:GHRS GH Research (GHRS) Stock Price, News & Analysis $9.40 -0.13 (-1.36%) Closing price 04:00 PM EasternExtended Trading$9.40 -0.01 (-0.05%) As of 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About GH Research Stock (NASDAQ:GHRS) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get GH Research alerts:Sign Up Key Stats Today's Range$9.30▼$10.0050-Day Range$8.66▼$13.9952-Week Range$6.00▼$20.50Volume120,391 shsAverage Volume173,594 shsMarket Capitalization$489.06 millionP/E RatioN/ADividend YieldN/APrice Target$30.86Consensus RatingBuy Company OverviewGH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). The company's lead program is GH001, an inhalable mebufotenin product candidate, currently under Phase 2b clinical trial for the treatment of patients with TRD, as well as Phase 2a clinical trials for the treatment of Bipolar II disorder and postpartum depression. It is also involved in the development of GH002, an intravenous mebufotenin product candidate for IV administration, currently under Phase 1 clinical trials for the treatment of psychiatric or neurological disorder; and GH003, an intranasal mebufotenin product candidate for nasal administration, which is currently in preclinical development with a focus on psychiatric and neurological disorders. The company was founded in 2018 and is based in Dublin, Ireland.Read More… GH Research Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks41st Percentile Overall ScoreGHRS MarketRank™: GH Research scored higher than 41% of companies evaluated by MarketBeat, and ranked 467th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingGH Research has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageGH Research has only been the subject of 4 research reports in the past 90 days.Read more about GH Research's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for GH Research are expected to decrease in the coming year, from ($0.80) to ($1.05) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of GH Research is -11.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of GH Research is -11.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about GH Research's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted7.12% of the float of GH Research has been sold short.Short Interest Ratio / Days to CoverGH Research has a short interest ratio ("days to cover") of 5.7.Change versus previous monthShort interest in GH Research has recently increased by 3.97%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldGH Research does not currently pay a dividend.Dividend GrowthGH Research does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted7.12% of the float of GH Research has been sold short.Short Interest Ratio / Days to CoverGH Research has a short interest ratio ("days to cover") of 5.7.Change versus previous monthShort interest in GH Research has recently increased by 3.97%, indicating that investor sentiment is decreasing. News and Social Media3.0 / 5News Sentiment1.33 News SentimentGH Research has a news sentiment score of 1.33. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.85 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for GH Research this week, compared to 3 articles on an average week.MarketBeat FollowsOnly 2 people have added GH Research to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, GH Research insiders have not sold or bought any company stock.Percentage Held by Insiders41.60% of the stock of GH Research is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions56.90% of the stock of GH Research is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about GH Research's insider trading history. Receive GHRS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for GH Research and its competitors with MarketBeat's FREE daily newsletter. Email Address GHRS Stock News HeadlinesGH Research initiated with a Buy at GuggenheimMarch 12, 2025 | markets.businessinsider.comGuggenheim starts GH Research at Buy, sees long-term upside potentialMarch 12, 2025 | markets.businessinsider.comMassive red flag about American consumerWhy is the U.S. Dollar suddenly crashing? Pundits on either side of the aisle have been warning that the U.S. dollar would crash for years. In 2025, it looks like it finally is. What does that mean for you money... and was this President Trump's plan all along? A widely followed 25-year economist and investor explains exactly what's happening, what could come next, and how to position your money on this page here.April 28, 2025 | Stansberry Research (Ad)RBC Capital Initiates Coverage of GH Research (GHRS) with Outperform RecommendationMarch 8, 2025 | msn.comGH Research initiated with an Outperform at RBC CapitalMarch 7, 2025 | markets.businessinsider.comGH Research PLC (GHRS): Among the Best Psychedelic Stocks to Buy in 2025March 1, 2025 | insidermonkey.comGH Research PLC: GH Research Reports Full Year 2024 Financial Results and Provides Business UpdatesFebruary 27, 2025 | finanznachrichten.dePsychedelic: GH Research, Compass Pathways report earnings resultsFebruary 27, 2025 | markets.businessinsider.comSee More Headlines GHRS Stock Analysis - Frequently Asked Questions How have GHRS shares performed this year? GH Research's stock was trading at $7.00 at the start of the year. Since then, GHRS stock has increased by 34.3% and is now trading at $9.40. View the best growth stocks for 2025 here. How were GH Research's earnings last quarter? GH Research PLC (NASDAQ:GHRS) announced its quarterly earnings results on Thursday, February, 27th. The company reported ($0.17) earnings per share for the quarter, beating the consensus estimate of ($0.23) by $0.06. When did GH Research IPO? GH Research (GHRS) raised $150 million in an initial public offering on Friday, June 25th 2021. The company issued 10,000,000 shares at $14.00-$16.00 per share. Who are GH Research's major shareholders? GH Research's top institutional shareholders include Palumbo Wealth Management LLC (0.02%). How do I buy shares of GH Research? Shares of GHRS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of GH Research own? Based on aggregate information from My MarketBeat watchlists, some other companies that GH Research investors own include Baidu (BIDU), Shopify (SHOP), Bristol-Myers Squibb (BMY), Zoom Video Communications (ZM), Atai Life Sciences (ATAI), CRISPR Therapeutics (CRSP) and Caesars Entertainment (CZR). Company Calendar Last Earnings2/27/2025Today4/28/2025Next Earnings (Estimated)5/02/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:GHRS CIK1855129 Webwww.ghres.com Phone212-450-4000FaxN/AEmployees10Year FoundedN/APrice Target and Rating Average Stock Price Target$30.86 High Stock Price Target$40.00 Low Stock Price Target$14.00 Potential Upside/Downside+228.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($0.75) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-35,590,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-20.29% Return on Assets-19.49% Debt Debt-to-Equity RatioN/A Current Ratio15.83 Quick Ratio15.83 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares52,028,000Free Float30,384,000Market Cap$489.06 million OptionableOptionable Beta0.84 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.Get This Free Report This page (NASDAQ:GHRS) was last updated on 4/28/2025 by MarketBeat.com Staff From Our PartnersURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored‘Wheels Are Falling Off’ the U.S. Stock MarketThe last time the U.S. economy looked like this, stocks didn't move for 16 years... And many investors lost...Stansberry Research | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredM.A.G.A. is Finished – This Could be even BetterYou’ve no doubt heard Trump’s rally cry: Make America Great Again. But recently the President made a big ch...Paradigm Press | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredHere’s How to Claim Your Stake in Elon’s Private Company, xAII predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GH Research PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share GH Research With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.